Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Forwards Specialty Strategy With $576m Concert Acquisition

Sun’s Nabs Concert, Picking Up Firm’s ‘Potential Best-In-Class’ Deuruxolitinib

Executive Summary

Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.

You may also be interested in...



Sun Pharma Reinforces Position As Indian Industry Leader

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Concert’s Patient-Reported Outcome Could Help Differentiate Its Alopecia Therapy

Concert’s CTP-543 would be second or third to market in alopecia areata, behind Lilly and likely Pfizer, but the biotech thinks its drug will have the best profile based on efficacy and patient satisfaction.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel